Arthrocolins Synergizing with Fluconazole Inhibit Fluconazole-Resistant Candida albicans by Increasing Riboflavin Metabolism and Causing Mitochondrial Dysfunction and Autophagy

Zhuang Wu,Qun-Fu Wu,Wen-Li Yuan,Yong-Hong Chen,Di Hu,De-Yao Deng,Long-Long Zhang,Xue-Mei Niu

DOI: https://doi.org/10.1128/spectrum.04051-22

IF: 3.7

2023-04-13

Microbiology Spectrum

Abstract:The prevalence of antifungal-resistant Candida albicans , which is a common human fungal pathogen causing life-threatening systemic infections, has become a challenge in the treatment of fungal infections. Arthrocolins are a new type of xanthene obtained from Escherichia coli fed with a key fungal precursor toluquinol.

microbiology

What problem does this paper attempt to address?

The paper primarily discusses how arthrocolins—a novel compound obtained from Escherichia coli—works in synergy with fluconazole, a commonly used antifungal drug, to inhibit the growth of drug-resistant Candida albicans. The study indicates that arthrocolins can enhance the antimicrobial activity of fluconazole against drug-resistant Candida albicans. This synergistic effect is achieved by increasing the permeability of the fungal cell membrane, allowing arthrocolins to enter the cell and subsequently cause mitochondrial dysfunction, increased autophagy, elevated levels of reactive oxygen species (ROS), and lipid accumulation, ultimately leading to fungal death.

Specifically, the combined use of arthrocolins with fluconazole significantly reduces the pathogenicity of Candida albicans, which has been validated in both in vitro experiments (such as the 293T human cell infection model) and in vivo experiments (such as the Caenorhabditis elegans infection model). The study also found that this combination therapy can induce an increase in fungal cell membrane permeability, promote the intracellular accumulation of arthrocolins, affect the structure of the fungal cell wall, and cause a reduction in the number and function of mitochondria.

From a molecular mechanism perspective, after the combined use of arthrocolins with fluconazole, there is an upregulation of riboflavin metabolism pathways and proteasome activity, and a downregulation of gene expression related to fungal pathogenicity. This leads to the inhibition of protein biosynthesis, an increase in ROS and lipid levels, triggering of the autophagy process, and ultimately resulting in fungal death. These findings provide a new perspective and theoretical basis for the development of novel antifungal drugs.